365 related articles for article (PubMed ID: 24860567)
1. Does the immune system naturally protect against cancer?
Corthay A
Front Immunol; 2014; 5():197. PubMed ID: 24860567
[TBL] [Abstract][Full Text] [Related]
2. Squamous-cell carcinoma, Kaposi's sarcoma and Burkitt's lymphoma are consequences of impaired immune surveillance of ubiquitous viruses in acquired immune deficiency syndrome, allograft recipients and tropical African patients.
Purtilo DT; Manolov G; Manolova Y; Harada S; Lipscomb H
IARC Sci Publ; 1984; (63):749-70. PubMed ID: 6100288
[TBL] [Abstract][Full Text] [Related]
3. Cancer immunoediting: from immunosurveillance to tumor escape.
Dunn GP; Bruce AT; Ikeda H; Old LJ; Schreiber RD
Nat Immunol; 2002 Nov; 3(11):991-8. PubMed ID: 12407406
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Blockade in Breast Cancer Therapy.
Bu X; Yao Y; Li X
Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibitors in Organ Transplant Patients.
Kittai AS; Oldham H; Cetnar J; Taylor M
J Immunother; 2017 Sep; 40(7):277-281. PubMed ID: 28719552
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy.
Adachi K; Tamada K
Cancer Sci; 2015 Aug; 106(8):945-50. PubMed ID: 25981182
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
Hargadon KM; Johnson CE; Williams CJ
Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitors in the management of malignancies in transplant recipients.
Regalla DKR; Williams GR; Paluri RK
Postgrad Med J; 2018 Dec; 94(1118):704-708. PubMed ID: 30425139
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic gene modified cell based cancer vaccines.
Kozłowska A; Mackiewicz J; Mackiewicz A
Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease.
Srinivasan P; Wu X; Basu M; Rossi C; Sandler AD
PLoS Med; 2018 Jan; 15(1):e1002497. PubMed ID: 29377881
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint blockade therapy.
Wieder T; Eigentler T; Brenner E; Röcken M
J Allergy Clin Immunol; 2018 Nov; 142(5):1403-1414. PubMed ID: 29596939
[TBL] [Abstract][Full Text] [Related]
12. Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules.
D'Arrigo P; Tufano M; Rea A; Vigorito V; Novizio N; Russo S; Romano MF; Romano S
Curr Med Chem; 2020; 27(15):2402-2448. PubMed ID: 30398102
[TBL] [Abstract][Full Text] [Related]
13. Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer.
Fiegle E; Doleschel D; Koletnik S; Rix A; Weiskirchen R; Borkham-Kamphorst E; Kiessling F; Lederle W
Neoplasia; 2019 Sep; 21(9):932-944. PubMed ID: 31412307
[TBL] [Abstract][Full Text] [Related]
14. Cancer Immunosurveillance by T Cells.
Rao S; Gharib K; Han A
Int Rev Cell Mol Biol; 2019; 342():149-173. PubMed ID: 30635090
[TBL] [Abstract][Full Text] [Related]
15. Development of Cancer Immunotherapy Targeting the PD-1 Pathway.
Kamimura N; Wolf AM; Iwai Y
J Nippon Med Sch; 2019; 86(1):10-14. PubMed ID: 30918149
[TBL] [Abstract][Full Text] [Related]
16. Application of PD-1 Blockade in Cancer Immunotherapy.
Wu X; Gu Z; Chen Y; Chen B; Chen W; Weng L; Liu X
Comput Struct Biotechnol J; 2019; 17():661-674. PubMed ID: 31205619
[TBL] [Abstract][Full Text] [Related]
17. Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.
Reardon DA; Gokhale PC; Klein SR; Ligon KL; Rodig SJ; Ramkissoon SH; Jones KL; Conway AS; Liao X; Zhou J; Wen PY; Van Den Abbeele AD; Hodi FS; Qin L; Kohl NE; Sharpe AH; Dranoff G; Freeman GJ
Cancer Immunol Res; 2016 Feb; 4(2):124-35. PubMed ID: 26546453
[TBL] [Abstract][Full Text] [Related]
18. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
[TBL] [Abstract][Full Text] [Related]
19. Heating it up: Oncolytic viruses make tumors 'hot' and suitable for checkpoint blockade immunotherapies.
Gujar S; Pol JG; Kroemer G
Oncoimmunology; 2018; 7(8):e1442169. PubMed ID: 30221036
[TBL] [Abstract][Full Text] [Related]
20. PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients.
Hossain MS; Kunter GM; El-Najjar VF; Jaye DL; Al-Kadhimi Z; Taofeek OK; Li JM; Waller EK
PLoS One; 2017; 12(9):e0184254. PubMed ID: 28953925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]